Top

Published in:

Open Access 01-12-2012 | Research article

UCHL1 S18Y variant is a risk factor for Parkinson’s disease in Japan

Authors: Yoshihiro Miyake, Keiko Tanaka, Wakaba Fukushima, Chikako Kiyohara, Satoshi Sasaki, Yoshio Tsuboi, Tatsuo Yamada, Tomoko Oeda, Hiroyuki Shimada, Nobutoshi Kawamura, Nobutaka Sakae, Hidenao Fukuyama, Yoshio Hirota, Masaki Nagai, the Fukuoka Kinki Parkinson’s Disease Study Group

Published in: BMC Neurology | Issue 1/2012

Abstract

Background

A recent meta-analysis on the UCHL1 S18Y variant and Parkinson’s disease (PD) showed a significant inverse association between the Y allele and PD; the individual studies included in that meta-analysis, however, have produced conflicting results. We examined the relationship between UCHL1 S18Y single nucleotide polymorphism (SNP) and sporadic PD in Japan.

Methods

Included were 229 cases within 6 years of onset of PD, defined according to the UK PD Society Brain Bank clinical diagnostic criteria. Controls were 357 inpatients and outpatients without neurodegenerative disease. Adjustment was made for sex, age, region of residence, smoking, and caffeine intake.

Results

Compared with subjects with the CC or CA genotype of UCHL1 S18Y SNP, those with the AA genotype had a significantly increased risk of sporadic PD: the adjusted OR was 1.57 (95 % CI: 1.06 − 2.31). Compared with subjects with the CC or CA genotype of UCHL1 S18Y and the CC or CT genotype of SNCA SNP rs356220, those with the AA genotype of UCHL1 S18Y and the TT genotype of SNP rs356220 had a significantly increased risk of sporadic PD; the interaction, however, was not significant. Our previous investigation found significant inverse relationships between smoking and caffeine intake and PD in this population. There were no significant interactions between UCHL1 S18Y and smoking or caffeine intake affecting sporadic PD.

Conclusions

This study reveals that the UCHL1 S18Y variant is a risk factor for sporadic PD. We could not find evidence for interactions affecting sporadic PD between UCHL1 S18Y and SNCA SNP rs356220, smoking, or caffeine intake.

Cook C, Petrucelli L: A critical evaluation of the ubiquitin-proteasome system in Parkinson's disease. Biochim Biophys Acta. 2009, 1792: 664-675. 10.1016/j.bbadis.2009.01.012.CrossRefPubMedPubMedCentral

Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J: The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science. 1989, 246: 670-673. 10.1126/science.2530630.CrossRefPubMed

Larsen CN, Krantz BA, Wilkinson KD: Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry. 1998, 37: 3358-3368. 10.1021/bi972274d.CrossRefPubMed

Cartier AE, Djakovic SN, Salehi A, Wilson SM, Masliah E, Patrick GN: Regulation of synaptic structure by ubiquitin C-terminal hydrolase L1. J Neurosci. 2009, 29: 7857-7868. 10.1523/JNEUROSCI.1817-09.2009.CrossRefPubMedPubMedCentral

Ragland M, Hutter C, Zabetian C, Edwards K: Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis. Am J Epidemiol. 2009, 170: 1344-1357. 10.1093/aje/kwp288.CrossRefPubMedPubMedCentral

Zhang J, Hattori N, Leroy E, Morris HR, Kubo S, Kobayashi T, Wood NW, Polymeropoulos MH, Mizuno Y: Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkinsonism Relat Disord. 2000, 6: 195-197. 10.1016/S1353-8020(00)00015-8.CrossRefPubMed

Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, Kanazawa I, Toda T: Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol. 2002, 51: 133-136. 10.1002/ana.10079.CrossRefPubMed

Wang J, Zhao CY, Si YM, Liu ZL, Chen B, Yu L: ACT and UCH-L1 polymorphisms in Parkinson's disease and age of onset. Mov Disord. 2002, 17: 767-771. 10.1002/mds.10179.CrossRefPubMed

Mizuta I, Satake W, Nakabayashi Y, Ito C, Suzuki S, Momose Y, Nagai Y, Oka A, Inoko H, Fukae J, Saito Y, Sawabe M, Murayama S, Yamamoto M, Hattori N, Murata M, Toda T: Multiple candidate gene analysis identifies α-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet. 2006, 15: 1151-1158. 10.1093/hmg/ddl030.CrossRefPubMed

10.

Tan EK, Puong KY, Fook-Chong S, Chua E, Shen H, Yuen Y, Pavanni R, Wong MC, Puvan K, Zhao Y: Case–control study of UCHL1 S18Y variant in Parkinson's disease. Mov Disord. 2006, 21: 1765-1768. 10.1002/mds.21064.CrossRefPubMed

11.

Maraganore DM, Farrer MJ, Hardy JA, Lincoln SJ, McDonnell SK, Rocca WA: Case–control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology. 1999, 53: 1858-1860. 10.1212/WNL.53.8.1858.CrossRefPubMed

12.

Wintermeyer P, Krüger R, Kuhn W, Müller T, Woitalla D, Berg D, Becker G, Leroy E, Polymeropoulos M, Berger K, Przuntek H, Schöls L, Epplen JT, Riess O: Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. NeuroReport. 2000, 11: 2079-2082. 10.1097/00001756-200007140-00004.CrossRefPubMed

13.

Mellick GD, Silburn PA: The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson's disease. Neurosci Lett. 2000, 293: 127-130. 10.1016/S0304-3940(00)01510-X.CrossRefPubMed

14.

Levecque C, Destée A, Mouroux V, Becquet E, Defebvre L, Amouyel P, Chartier-Harlin MC: No genetic association of the ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson's disease. J Neural Transm. 2001, 108: 979-984. 10.1007/s007020170017.CrossRefPubMed

15.

Savettieri G, De Marco EV, Civitelli D, Salemi G, Nicoletti G, Annesi G, Cirò Candiano IC, Quattron A: Lack of association between ubiquitin carboxy-terminal hydrolase L1 gene polymorphism and PD. Neurology. 2001, 57: 560-561. 10.1212/WNL.57.3.560.CrossRefPubMed

16.

Elbaz A, Levecque C, Clavel J, Vidal JS, Richard F, Corrèze JR, Delemotte B, Amouyel P, Alpérovitch A, Chartier-Harlin MC, Tzourio C: S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: evidence for an age-dependent relationship. Mov Disord. 2003, 18: 130-137. 10.1002/mds.10326.CrossRefPubMed

17.

Facheris M, Strain KJ, Lesnick TG, de Andrade M, Bower JH, Ahlskog JE, Cunningham JM, Lincoln S, Farrer MJ, Rocca WA, Maraganore DM: UCHL1 is associated with Parkinson's disease: a case-unaffected sibling and case-unrelated control study. Neurosci Lett. 2005, 381: 131-134. 10.1016/j.neulet.2005.02.008.CrossRefPubMed

18.

Healy DG, Abou-Sleiman PM, Casas JP, Ahmadi KR, Lynch T, Gandhi S, Muqit MM, Foltynie T, Barker R, Bhatia KP, Quinn NP, Lees AJ, Gibson JM, Holton JL, Revesz T, Goldstein DB, Wood NW: UCHL-1 is not a Parkinson's disease susceptibility gene. Ann Neurol. 2006, 59: 627-633. 10.1002/ana.20757.CrossRefPubMed

19.

Carmine Belin A, Westerlund M, Bergman O, Nissbrandt H, Lind C, Sydow O, Galter D: S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson's disease in Sweden. Parkinsonism Relat Disord. 2007, 13: 295-298. 10.1016/j.parkreldis.2006.12.002.CrossRefPubMed

20.

Hutter CM, Samii A, Factor SA, Nutt JG, Higgins DS, Bird TD, Griffith A, Roberts JW, Leis BC, Montimurro JS, Kay DM, Edwards KL, Payami H, Zabetian CP: Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease. Eur J Neurol. 2008, 15: 134-139.CrossRefPubMed

21.

Zhang ZJ, Burgunder JM, An XK, Wu Y, Chen WJ, Zhang JH, Wang YC, Xu YM, Gou YR, Yuan GG, Mao XY, Peng R: Lack of evidence for association of a UCH-L1 S18Y polymorphism with Parkinson's disease in a Han-Chinese population. Neurosci Lett. 2008, 442: 200-202. 10.1016/j.neulet.2008.07.012.CrossRefPubMed

22.

Wu YR, Chen CM, Chen YC, Chao CY, Ro LS, Fung HC, Hsiao YC, Hu FJ, Lee-Chen GJ: Ubiquitin specific proteases USP24 and USP40 and ubiquitin thiolesterase UCHL1 polymorphisms have synergic effect on the risk of Parkinson's disease among Taiwanese. Clin Chim Acta. 2010, 411: 955-958. 10.1016/j.cca.2010.03.013.CrossRefPubMed

23.

Wang L, Guo JF, Nie LL, Luo L, Zuo X, Shen L, Jiang H, Yan XX, Xia K, Pan Q, Tang BS: Case–control study of the UCH-L1 S18Y variant in sporadic Parkinson's disease in the Chinese population. J Clin Neurosci. 2011, 18: 541-544. 10.1016/j.jocn.2010.07.142.CrossRefPubMed

24.

Tan EK, Lu CS, Peng R, Teo YY, Wu-Chou YH, Chen RS, Weng YH, Chen CM, Fung HC, Tan LC, Zhang ZJ, An XK, Lee-Chen GJ, Lee MC, Fook-Chong S, Burgunder JM, Wu RM, Wu YR: Analysis of the UCHL1 genetic variant in Parkinson's disease among Chinese. Neurobiol Aging. 2010, 31: 2194-2196. 10.1016/j.neurobiolaging.2008.11.008.CrossRefPubMed

25.

Snapinn KW, Larson EB, Kawakami H, Ujike H, Borenstein AR, Izumi Y, Kaji R, Maruyama H, Mata IF, Morino H, Oda M, Tsuang DW, Yearout D, Edwards KL, Zabetian CP: The UCHL1 S18Y polymorphism and Parkinson's disease in a Japanese population. Parkinsonism Relat Disord. 2011, 17: 473-475. 10.1016/j.parkreldis.2011.01.019.CrossRefPubMedPubMedCentral

26.

Yasuda T, Nihira T, Ren YR, Cao XQ, Wada K, Setsuie R, Kabuta T, Wada K, Hattori N, Mizuno Y, Mochizuki H: Effects of UCH-L1 on α-synuclein over-expression mouse model of Parkinson's disease. J Neurochem. 2009, 108: 932-944. 10.1111/j.1471-4159.2008.05827.x.CrossRefPubMed

27.

Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992, 55: 181-184. 10.1136/jnnp.55.3.181.CrossRefPubMedPubMedCentral

28.

Miyake Y, Tanaka K, Fukushima W, Kiyohara C, Sasaki S, Tsuboi Y, Yamada T, Oeda T, Shimada H, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M, Fukuoka Kinki Parkinson’s Disease Study Group: SNCA polymorphisms, smoking, and sporadic Parkinson’s disease in Japanese. Parkinsonism Relat Disord. 2012, 18: 557-561. 10.1016/j.parkreldis.2012.02.016.CrossRefPubMed

29.

Tanaka K, Miyake Y, Fukushima W, Sasaki S, Kiyohara C, Tsuboi Y, Yamada T, Oeda T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M, Fukuoka Kinki Parkinson’s Disease Study Group: Active and passive smoking and risk of Parkinson’s disease. Acta Neurol Scand. 2010, 122: 377-382. 10.1111/j.1600-0404.2010.01327.x.CrossRefPubMed

30.

Tanaka K, Miyake Y, Fukushima W, Sasaki S, Kiyohara C, Tsuboi Y, Yamada T, Oeda T, Miki T, Kawamura N, Sakae N, Fukuyama H, Hirota Y, Nagai M, Fukuoka Kinki Parkinson’s Disease Study Group: Intake of Japanese and Chinese teas reduces risk of Parkinson’s disease. Parkinsonism Relat Disord. 2011, 17: 446-450. 10.1016/j.parkreldis.2011.02.016.CrossRefPubMed

31.

Andersson T, Alfredsson L, Källberg H, Zdravkovic S, Ahlbom A: Calculating measures of biological interaction. Eur J Epidemiol. 2005, 20: 575-579. 10.1007/s10654-005-7835-x.CrossRefPubMed

32.

Knol MJ, VanderWeele TJ, Groenwold RH, Klungel OH, Rovers MM, Grobbee DE: Estimating measures of interaction on an additive scale for preventive exposures. Eur J Epidemiol. 2011, 26: 433-438. 10.1007/s10654-011-9554-9.CrossRefPubMedPubMedCentral

33.

Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, Schjeide LM, Meissner E, Zauft U, Allen NC, Liu T, Schilling M, Anderson KJ, Beecham G, Berg D, Biernacka JM, Brice A, DeStefano AL, Do CB, Eriksson N, Factor SA, Farrer MJ, Foroud T, Gasser T, Hamza T, Hardy JA, Heutink P, Hill-Burns EM, Klein C, Latourelle JC, et al: Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database. PLoS Genet. 2012, 8: e1002548-10.1371/journal.pgen.1002548.CrossRefPubMedPubMedCentral

34.

Satake W, Nakabayashi Y, Mizuta I, Hirota Y, Ito C, Kubo M, Kawaguchi T, Tsunoda T, Watanabe M, Takeda A, Tomiyama H, Nakashima K, Hasegawa K, Obata F, Yoshikawa T, Kawakami H, Sakoda S, Yamamoto M, Hattori N, Murata M, Nakamura Y, Toda T: Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat Genet. 2009, 41: 1303-1307. 10.1038/ng.485.CrossRefPubMed

35.

Andersson FI, Werrell EF, McMorran L, Crone WJ, Das C, Hsu ST, Jackson SE: The effect of Parkinson's-disease-associated mutations on the deubiquitinating enzyme UCH-L1. J Mol Biol. 2011, 407: 261-272. 10.1016/j.jmb.2010.12.029.CrossRefPubMed

36.

Carolan BJ, Heguy A, Harvey BG, Leopold PL, Ferris B, Crystal RG: Up-regulation of expression of the ubiquitin carboxyl-terminal hydrolase L1 gene in human airway epithelium of cigarette smokers. Cancer Res. 2006, 66: 10729-10740. 10.1158/0008-5472.CAN-06-2224.CrossRefPubMed

37.

McCulloch CC, Kay DM, Factor SA, Samii A, Nutt JG, Higgins DS, Griffith A, Roberts JW, Leis BC, Montimurro JS, Zabetian CP, Payami H: Exploring gene-environment interactions in Parkinson's disease. Hum Genet. 2008, 123: 257-265. 10.1007/s00439-008-0466-z.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/12/62/prepub

Title: UCHL1 S18Y variant is a risk factor for Parkinson’s disease in Japan
Authors: Yoshihiro Miyake
Keiko Tanaka
Wakaba Fukushima
Chikako Kiyohara
Satoshi Sasaki
Yoshio Tsuboi
Tatsuo Yamada
Tomoko Oeda
Hiroyuki Shimada
Nobutoshi Kawamura
Nobutaka Sakae
Hidenao Fukuyama
Yoshio Hirota
Masaki Nagai
the Fukuoka Kinki Parkinson’s Disease Study Group
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: BMC Neurology / Issue 1/2012
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/1471-2377-12-62

Keynote webinar | Spotlight on medication adherence

Springer Medicine

UCHL1 S18Y variant is a risk factor for Parkinson’s disease in Japan

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study

Oxidative stress markers are associated to vascular recurrence in non-cardioembolic stroke patients non-treated with statins

Neurosyphilis with dementia and bilateral hippocampal atrophy on brain magnetic resonance imaging

Sleep problems in Parkinson’s disease: a community-based study in Norway

Rationale and design of a double-blind, placebo-controlled, randomized trial to evaluate the safety and efficacy of nimodipine in preventing cognitive impairment in ischemic cerebrovascular events (NICE)

How to improve walking, balance and social participation following stroke: a comparison of the long term effects of two walking aids--canes and an orthosis TheraTogs--on the recovery of gait following acute stroke. A study protocol for a multi-centre, single blind, randomised control trial